Canakinumab Treatment in Familial Mediterranean Fever Patients: With/Without Colchicine
It is difficult to make a recommendation regarding the discontinuation or continuation of colchicine treatment in all FMF patients who initiated anti-IL-1 treatment. Canakinumab can be continued as monotherapy in patients who cannot continue colchicine treatment due to side effects and patient noncompliance.
Authors
- Funda Erbasan (ORCID: https://orcid.org/0000-0001-9960-5664)
- Tahir Öğüt (ORCID: https://orcid.org/0000-0003-4189-3717)
- Mine Nokay (ORCID: https://orcid.org/0000-0001-5442-0121)
- Melis Dilbil (ORCID: https://orcid.org/0000-0002-5287-0556)
- Veli Yazısız (ORCID: https://orcid.org/0000-0002-3176-4850)
- Mustafa Ender Terzioğlu (ORCID: https://orcid.org/0000-0002-1228-7323)
Institutions
- Akdeniz University (TR)
- Antalya IVF (TR)
Publication Details
- Journal
- International Journal of Rheumatic Diseases
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1111/1756-185x.70159
- Citations
- 1
- Primary Topic
- Inflammasome and immune disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.81